Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Yin, Ji Ye ^a   Huang, Qiong ^b   Zhao, Ying Chun ^c   Zhou, Hong Hao ^a   Liu, Zhao Qian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLATINUM COMPLEX;

ARTICLE; ASIAN; CANCER CHEMOTHERAPY; DATA EXTRACTION; ERCC1 GENE; GENE; GENETIC IDENTIFICATION; GENETIC POLYMORPHISM; GSTM1 GENE; GSTP1 GENE; HUMAN; LUNG NON SMALL CELL CANCER; MDR1 GENE; META ANALYSIS; PHARMACOGENETICS; RRM1 GENE; SYSTEMATIC REVIEW; XPD GENE; XPG GENE; XRCC1 GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; PHARMACOGENETICS; PLATINUM; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862739890     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038150     Document Type: Article

References (72)

1. Herbst RS, Heymach JV, Lippman SM, (2008) Lung cancer. N Engl J Med 359: 1367-1380.
2. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
3. Kweekel DM, Gelderblom H, Guchelaar HJ, (2005) Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat Rev 31: 90-105.
4. Yu M, Xu XJ, Yin JY, Wu J, Chen X, et al. (2010) KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes. Clin Pharmacol Ther 87: 330-335.
5. Huang Q, Yin JY, Dai XP, Wu J, Chen X, et al. (2010) Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients. Eur J Clin Pharmacol 66: 1207-1215.
6. Su D, Ma S, Liu P, Jiang Z, Lv W, et al. (2007) Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer 56: 281-288.
7. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, et al. (2008) Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 14: 1797-1803.
8. Isla D, Sarries C, Rosell R, Alonso G, Domine M, et al. (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15: 1194-1203.
9. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, et al. (2009) DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer 10: 118-123.
10. Sun N, Sun X, Chen B, Cheng H, Feng J, et al. (2010) MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 65: 437-446.
11. Booton R, Ward T, Heighway J, Ashcroft L, Morris J, et al. (2006) Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. J Thorac Oncol 1: 679-683.
12. Hildebrandt MA, Gu J, Wu X, (2009) Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol 5: 745-755.
13. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
14. Lau J, Ioannidis JP, Schmid CH, (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820-826.
15. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
16. DerSimonian R, Kacker R, (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28: 105-114.
17. Mantel N, Haenszel W, (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748.
18. Begg CB, Mazumdar M, (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
19. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
20. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S, (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73: 39-85.
21. Garcia-Campelo R, Alonso-Curbera G, Anton Aparicio LM, Rosell R, (2005) Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy. Expert Opin Pharmacother 6: 2015-2026.
22. Yu D, Zhang X, Liu J, Yuan P, Tan W, et al. (2008) Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res 14: 2878-2886.
23. Sun X, Li F, Sun N, Shukui Q, Baoan C, et al. (2009) Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients. Lung Cancer 65: 230-236.
24. Feng J, Sun X, Sun N, Qin S, Li F, et al. (2009) XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer. Acta Biochim Biophys Sin (Shanghai) 41: 429-435.
25. Yin JY, Huang Q, Yang Y, Zhang JT, Zhong MZ, et al. (2009) Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics 19: 206-216.
26. Yin J, Zhang J, (2011) Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application. Zhong Nan Da Xue Xue Bao Yi Xue Ban 36: 927-938.
27. Yin JY, Han LF, Huang Q, Xu XJ, Zhou HH, et al. (2011) ABCC1 polymorphism Arg723Gln (2168G& A) is associated with lung cancer susceptibility in a Chinese population. Clin Exp Pharmacol Physiol 38: 632-637.
28. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM, (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234.
29. Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM, (2008) The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48: 495-535.
30. Woodahl EL, Ho RJ, (2004) The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 5: 11-19.
31. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, et al. (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528.
32. Pan JH, Han JX, Wu JM, Huang HN, Yu QZ, et al. (2009) MDR1 single nucleotide polymorphism G2677T/A and haplotype are correlated with response to docetaxel-cisplatin chemotherapy in patients with non-small-cell lung cancer. Respiration 78: 49-55.
33. Watson MA, Stewart RK, Smith GB, Massey TE, Bell DA, (1998) Human glutathione S-transferase P1 polymorphisms: relationship to lung tissue enzyme activity and population frequency distribution. Carcinogenesis 19: 275-280.
34. Stewart DJ, (2007) Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 63: 12-31.
35. Cheng H, Sun N, Sun X, Chen B, Li F, et al. (2010) Polymorphisms in hMSH2 and hMLH1 and response to platinum-based chemotherapy in advanced non-small-cell lung cancer patients. Acta Biochim Biophys Sin (Shanghai) 42: 311-317.
36. Feng JF, Wu JZ, Hu SN, Gao CM, Shi MQ, et al. (2009) Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer. Lung Cancer 66: 344-349.
37. Yu JJ, Lee KB, Mu C, Li Q, Abernathy TV, et al. (2000) Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene. Int J Oncol 16: 555-560.
38. Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, et al. (2001) A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61: 8654-8658.
39. Shiraishi K, Kohno T, Tanai C, Goto Y, Kuchiba A, et al. (2010) Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 28: 4945-4952.
40. Tan XL, Moyer AM, Fridley BL, Schaid DJ, Niu N, et al. (2011) Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin Cancer Res 17: 5801-5811.
41. Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, et al. (2011) Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. J Natl Cancer Inst 103: 817-825.
42. Li Y, Sun Z, Cunningham JM, Aubry MC, Wampfler JA, et al. (2011) Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy. Clin Cancer Res 17: 3830-3840.
43. Dolan ME, Newbold KG, Nagasubramanian R, Wu X, Ratain MJ, et al. (2004) Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res 64: 4353-4356.
44. Shukla SJ, Duan S, Badner JA, Wu X, Dolan ME, (2008) Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet Genomics 18: 253-262.
45. Huang RS, Duan S, Shukla SJ, Kistner EO, Clark TA, et al. (2007) Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 81: 427-437.
46. Huang RS, Duan S, Kistner EO, Hartford CM, Dolan ME, (2008) Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans. Mol Cancer Ther 7: 3038-3046.
47. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, et al. (2008) Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 40: 616-622.
48. Hung RJ, McKay JD, Gaborieau V, Boffetta P, Hashibe M, et al. (2008) A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 452: 633-637.
49. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, et al. (2008) A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 452: 638-642.
50. Link E, Parish S, Armitage J, Bowman L, Heath S, et al. (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 359: 789-799.
51. Gautschi O, Hugli B, Ziegler A, Bigosch C, Bowers NL, et al. (2006) Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients. Lung Cancer 51: 303-311.
52. Ishida S, Lee J, Thiele DJ, Herskowitz I, (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 99: 14298-14302.
53. Katano K, Kondo A, Safaei R, Holzer A, Samimi G, et al. (2002) Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res 62: 6559-6565.
54. Safaei R, Holzer AK, Katano K, Samimi G, Howell SB, (2004) The role of copper transporters in the development of resistance to Pt drugs. J Inorg Biochem 98: 1607-1613.
55. Wang D, Lippard SJ, (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320.
56. Yu D, Shi J, Sun T, Du X, Liu L, et al. (2012) Pharmacogenetic role of ERCC1 genetic variants in treatment response of platinum-based chemotherapy among advanced non-small cell lung cancer patients. Tumour Biol.
57. Wei HB, Lu XS, Shang LH, Xu G, Hu J, et al. (2011) Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Arch Med Res 42: 412-420.
58. Wei SZ, Zhan P, Shi MQ, Shi Y, Qian Q, et al. (2010) Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol.
59. Ryu JS, Hong YC, Han HS, Lee JE, Kim S, et al. (2004) Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44: 311-316.
60. Chen S, Huo X, Lin Y, Ban H, Li W, et al. (2010) Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health 213: 140-145.
61. Zhou C, Ren S, Zhou S, Zhang L, Su C, et al. (2010) Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients. Jpn J Clin Oncol 40: 954-960.
62. Li W, Yue W, Zhang L, Zhao X, Ma L, et al. (2012) Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response in non-small-cell lung cancer patients. Lung 190: 91-98.
63. Vinolas N, Provencio M, Reguart N, Cardenal F, Alberola V, et al. (2011) Single nucleotide polymorphisms in MDR1 gen correlates with outcome in advanced non-small-cell lung cancer patients treated with cisplatin plus vinorelbine. Lung Cancer 71: 191-198.
64. Cheng J, Ha M, Wang Y, Sun J, Chen J, et al. (2012) A C118T polymorphism of ERCC1 and response to cisplatin chemotherapy in patients with late-stage non-small cell lung cancer. J Cancer Res Clin Oncol 138: 231-238.
65. Li F, Sun X, Sun N, Qin S, Cheng H, et al. (2010) Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol 33: 489-494.
66. Booton R, Ward T, Heighway J, Taylor P, Power F, et al. (2006) Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer. Cancer 106: 2421-2427.
67. Camps C, Sarries C, Roig B, Sanchez JJ, Queralt C, et al. (2003) Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Lung Cancer 4: 237-241.
68. Yao CY, Huang XE, Li C, Shen HB, Shi MQ, et al. (2009) Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers. Asian Pac J Cancer Prev 10: 859-864.
69. Giachino DF, Ghio P, Regazzoni S, Mandrile G, Novello S, et al. (2007) Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer. Clin Cancer Res 13: 2876-2881.
70. Chen X, Sun H, Ren S, Kim Curran V, Zhang L, et al. (2012) Association of XRCC3 and XPD751 SNP with efficacy of platinum-based chemotherapy in advanced NSCLC patients. Clin Transl Oncol 14: 207-213.
71. Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, et al. (2008) MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer. Respiration 75: 380-385.
72. Zhou F, Yu Z, Jiang T, Lv H, Yao R, et al. (2011) Genetic polymorphisms of GSTP1 and XRCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. Swiss Med Wkly 141: w13275.